Camlin Fine Sciences subsidiary CFS Europe S.p.A. enters judicial liquidation proceedings
Camlin Fine Sciences subsidiary, CFS Europe S.p.A., has entered judicial liquidation proceedings as ordered by an Italian court on March 17, 2026. The subsidiary contributed 4.72% to CFS's turnover (₹7,873.81 Lakhs) and 9.73% to its net worth (₹8,512.36 Lakhs) as of March 31, 2025.
The judicial liquidation of a wholly owned subsidiary, which contributes a notable percentage to the company's turnover and net worth, is expected to have a significant impact on Camlin Fine Sciences Limited's overall financial health and operations.
The initiation of judicial liquidation proceedings for a wholly owned subsidiary indicates a significant negative event for the company, potentially impacting its financial performance and operational structure.
Camlin Fine Sciences Limited (CFS) announced on March 18, 2026, that its wholly owned subsidiary, CFS Europe S.p.A., has entered judicial liquidation proceedings. This follows an appeal filed by the Board of Statutory Auditors of CFS Europe S.p.A. with the Ordinary Court of Ravenna, Italy, on January 15, 2026.
The Court, in its order received on March 17, 2026, has officially initiated the liquidation proceedings under the Italian Code of Corporate Crisis and Insolvency. A delegated Judge and Court-appointed Liquidators (Curatori) have been appointed to manage the process.
As of March 31, 2025, CFS Europe S.p.A. contributed 4.72% to the company's turnover, amounting to ₹7,873.81 Lakhs. Its net worth was ₹8,512.36 Lakhs, representing 9.73% of the company's net worth. Further updates will be provided as material developments occur.
What to do with a filing like this
Camlin Fine Sciences Limited filed this with the NSE as a statutory disclosure, categorised under other corporate actions. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Camlin Fine Sciences Limited. Read the original for the full detail.